177Lu-PSMA-I&T/223Ra Display Safety and Feasibility in Metastatic CRPC
The PSA response rate and radiographic PFS were similar with the 177Lu-based combination regimen vs the radiotracer alone in metastatic CRPC.
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.
Career Stage and Location Found to Impact Oncology Coverage in the US
Rural populations and those with higher cancer burden and socioeconomic risk were found to have gaps in oncology care across the US.
Leveraging Biology to Advance the Small Cell Lung Cancer Treatment Paradigm
“Paradigm-changing events” are occurring across the small cell lung cancer field in real time, according to Anne Chiang, MD, PhD.
Pelareorep Combo Yields Responses in Squamous Cell Anal Carcinoma
Data from the phase 1/2 GOBLET trial show an objective response rate that exceeds a historical benchmark for second-line squamous cell anal carcinoma care.
What is the Impact of the SHARON Trial on Pancreatic Cancer Research?
Kenneth H. Yu, MD, discusses the results from the SHARON trial in pancreatic cancer that were presented at ESMO 2025.
